Annual Report · 10-K
Medicus Pharma Ltd.
MDCXNASDAQEQUITYCurrent
Annual Report
Company context
We are a clinical-stage, multi-strategy, life science and biotech company focused on investing in and accelerating the clinical development programs of novel and disruptive therapeutic assets. Currently, we are developing two products, SkinJectTM ("SkinJectTM"), with an indication for basal cell carcinoma, and Teverelix trifluoroacetate ("Teverelix", and together with SkinJectTM, the "Products").
Current securities
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗